Our
Success Stories
At BioAxis Partners, we are proud to have facilitated a range of high-impact licensing and sourcing deals across the pharmaceutical and biotech sectors. By connecting innovative companies in Europe and China, we help bring vital therapies to new markets, ensuring they reach patients in need.
Licensing an Oncology Biosimilar in China
A European biotech company sought a partner to license its oncology biosimilar for launch in China’s highly regulated market. BioAxis Partners facilitated this deal by identifying a reputable Chinese pharma company with robust distribution channels and a strong oncology focus. Through our guidance, the companies navigated regulatory requirements, tailored the biosimilar to local market needs, and launched successfully. This partnership has expanded the biotech’s presence in Asia and provides Chinese patients with affordable, innovative oncology care.
Bringing a CNS Small Molecule from China to Europe
BioAxis Partners played a pivotal role in helping a leading Chinese pharmaceutical company license a CNS (central nervous system) small molecule drug in Europe. We provided end-to-end support, from regulatory guidance and partner selection to commercialization strategy. The European partner’s strong track record in CNS drugs made it an ideal match, and the collaboration has introduced this innovative therapy to patients with unmet needs in Europe’s neurology market. This partnership also highlights the expanding pipeline of Chinese-originated drugs making a global impact.
Procuring API for a Major European Pharma
When a large European pharmaceutical company required a reliable source of high-quality active pharmaceutical ingredients (APIs), BioAxis Partners leveraged its extensive network to connect them with a trusted API manufacturer. We ensured the API supplier met European regulatory standards and could fulfill demand consistently. This sourcing success has enabled the pharma company to maintain high production standards, reduce lead times, and ensure the steady supply of essential medications to European markets.
